Table 1.
Sequential susceptibilities of Trichosporon asahii isolates to antifungal agents. Susceptibilities were estimated based on Candida albicans EUCAST breakpoints version 9.0 and provided as “indicative” to clinicians in absence of available breakpoints
| Tested antifungal agent | Isolate 1a | Isolate 2# | ||
|---|---|---|---|---|
| Minimal inhibitory concentrations (mg/L) | Susceptibility | Minimal inhibitory concentrations (mg/L) | Susceptibility | |
| Amphotericin B | 0.75 | Susceptible | 1.5 | Intermediate |
| Voriconazole | 0.023 | Susceptible | 0.023 | Susceptible |
| Isavuconazole | 0.023 | Susceptible | 0.047 | Susceptible |
| Flucytosine | 32 | Resistant | 32 | Resistant |
| Anidulafungin | 32 | Resistant | 32 | Resistant |
| Itraconazole | 0.5 | Resistant | 1.0 | Resistant |
| Posaconazole | 0.094 | Resistant | 0.094 | Resistant |
Notes: aIsolate 1 was obtained from blood culture 7 days after initiation of empiric caspofungin treatment (one month before isavuconazole therapy). Isolate 2 was obtained from cutaneous biopsy the day voriconazole therapy was stopped (12 days before isavuconazole therapy).